Guangzhou FineImmune Biotechnology Co.LTD.
tumor-specific TCR-T cells(Guangzhou FineImmune Biotechnology Co., LTD.)은 Solid Tumor 표적 세포·유전자 치료로, Solid Tumor 영역에서 개발·상용화 중입니다. 작용기전: Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 50% (ClinicalTrials.gov NCT01343043). 차별점: novel drug combination to enhance TCR therapy in mouse models for acute myeloid leukemia (AML) and multiple myeloma (MM).
Solid Tumor
Solid Tumor
Recruiting
CAR-T), tumor-infiltrating lymphocyte (TIL), and T cell receptor-
lipid nanoparticle delivery, we achieved efficient production of Allo-CAR T cells with high editin
novel drug combination to enhance TCR therapy in mouse models for acute myeloid leukemia (AML) and multiple myeloma (MM)
Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are critically evaluated
apoptosis and pyroptosis
biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to
escape, on-target off-tumor toxicity, and the suppressive features of the TME
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Guangzhou FineImmune Biotechnology Co.LTD.
tumor-specific TCR-T cells(Guangzhou FineImmune Biotechnology Co., LTD.)은 Solid Tumor 표적 세포·유전자 치료로, Solid Tumor 영역에서 개발·상용화 중입니다. 작용기전: Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 50% (ClinicalTrials.gov NCT01343043). 차별점: novel drug combination to enhance TCR therapy in mouse models for acute myeloid leukemia (AML) and multiple myeloma (MM).
Solid Tumor
Solid Tumor
Recruiting
CAR-T), tumor-infiltrating lymphocyte (TIL), and T cell receptor-
lipid nanoparticle delivery, we achieved efficient production of Allo-CAR T cells with high editin
novel drug combination to enhance TCR therapy in mouse models for acute myeloid leukemia (AML) and multiple myeloma (MM)
Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are critically evaluated
apoptosis and pyroptosis
biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to
escape, on-target off-tumor toxicity, and the suppressive features of the TME
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.